Dergiler / Molecular Imaging and Radionuclide Therapy / 2018 / Cilt: 27 - Sayı: 1

The Role of 18F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer

Meme Kanseri Tanısı ile Takip Edilmekte Olan Hastalarda Saptanan Tümör Belirteç Yüksekliğinin Değerlendirilmesinde 18F-FDG PET/BT’nin Rolü

Sayfa
3–9
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: In case of elevated levels of serum tumor markers, PET/CT has a high diagnostic accuracy in detecting tumor recurrence in patients with breast cancer, and it is an effective modality that can be used in addition to conventional imaging techniques.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Our aim was to assess the diagnostic performance of integrated positron emission tomography/computed tomography (PET/CT) in the follow-up of breast cancer patients, who underwent a PET/CT scan due to a suspicion of recurrence based on elevated levels of serum tumor markers.
📊
Temel Bulgular & Veri:PET/CT scan results were compared with the final diagnoses that were obtained from histopathological sampling or a minimum 6 months of radiological follow-up.
💡
Sonuç & Katkı:Conclusion: In case of elevated levels of serum tumor markers, PET/CT has a high diagnostic accuracy in detecting tumor recurrence in patients with breast cancer, and it is an effective modality that can be used in addition to conventional imaging techniques.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Our aim was to assess the diagnostic performance of integrated positron emission tomography/computed tomography (PET/CT) in the follow-up of breast cancer patients, who underwent a PET/CT scan due to a suspicion of recurrence based on elevated levels of serum tumor markers. Methods: Seventy-seven consecutive patients were included in this study. PET/CT scan results were compared with the final diagnoses that were obtained from histopathological sampling or a minimum 6 months of radiological follow-up. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and the diagnostic accuracy of PET/CT for detecting recurrence were calculated. Results: All 77 patients had increased serum cancer antigen 15-3 levels while 37 had increased serum carcinoembryonic antigen levels. According to PET/CT scan results, 59 of 77 patients (PET/CT positive) had local recurrence and/or distant metastasis while there was no pathological finding in 18 patients (PET/CT negative). In a follow-up of minimum 6 months, tumor recurrence was confirmed in 58 of “PET/CT positive” patients while no tumor recurrence was detected in 16 of “PET/ CT negative” patients. According to these results the sensitivity, specificity, PPV, NPV and the diagnostic accuracy of PET/CT for detecting recurrence on a per-person basis were calculated as 98%, 88%, 96%, 94% and 96%, respectively. Conclusion: In case of elevated levels of serum tumor markers, PET/CT has a high diagnostic accuracy in detecting tumor recurrence in patients with breast cancer, and it is an effective modality that can be used in addition to conventional imaging techniques.

Abstract

Amaç: Bu çalışmada meme kanseri tanısı ile takip edilmekte iken tümör belirteçlerinde [kanser antijeni (CA) 15-3 ve karsinoembriyonik antijen (CEA)] yükselme saptanan ve bu sebeple nüks şüphesiyle yeniden evreleme amacıyla 18F-FDG pozitron emisyon tomografi/bilgisayarlı tomografi (PET/BT) çekilen hastalarda PET/BT’nin tanısal etkinliği araştırıldı. Yöntem: Çalışmaya 77 hasta dahil edildi. Hastaların PET/BT sonuçları ile çalışma sonrası minimum 6 aylık takip döneminde elde edilen histopatolojik ve radyolojik veriler karşılaştırıldı. Bu sonuçlara göre PET/BT’nin duyarlılığı, özgüllüğü, pozitif prediktif değerleri (PPV) ve negatif prediktif değerleri (NPV) ile tanısal doğruluğu hesaplandı. Bulgular: Çalışmaya dahil edilen hastaların tamamında CA 15-3 düzeyi yüksek iken, CEA düzeyi 37 hastada yüksek idi. PET/ BT sonuçlarına göre 77 hastanın 59 tanesinde lokal nüks ve/veya uzak metastaz şüpheli lezyon saptanırken, 18 hastada herhangi bir patolojik bulguya rastlanmadı. Minimum 6 aylık takip neticesinde PET/BT’de şüpheli lezyon saptanan 59 hastanın 58 tanesinde lokal nüks ve/veya uzak metastaz varlığı doğrulanırken, PET/BT’de patolojik bulgu saptanmayan 18 hastanın 16 tanesinde takipleri süresince lokal nüks ve/veya uzak metastaz gelişmedi. Bu sonuçlara göre çalışmamızda PET/BT’nin hasta bazında duyarlılığı %96, özgüllüğü %94, PPV %98, NPV %88 ve tanısal doğruluğu %96 olarak bulundu. Sonuç: 18F-FDG PET/BT, meme kanseri tanısı ile takip edilmekte iken tümör belirteç yüksekliği saptanan hastalarda lokal nüks ve/veya uzak metastazın araştırılması için tanısal etkinliği yüksek non-invaziv ve konvansiyonel görüntüleme yöntemlerine ek olarak kullanılabilecek etkili bir görüntüleme yöntemidir.

🔖

Bu Makaleye Atıf Yap

GÖKTAŞ, İ., CAYVARLI, H. (2018). The Role of 18F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer. Molecular Imaging and Radionuclide Therapy, Cilt: 27 - Sayı: 1, 3–9. https://ajindex.com/articles/295082

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin 2015;65:87-108. Hayat MA. Methods of Cancer Diagnosis, Therapy, and Prognosis Volume 1, Breast Carcinoma. Springer; 2008.
  2. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008;13:447-451. O’Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer 1995;71:1288-1291.
  3. Samy N, Ragab HM, El Maksoud NA, Shaalan M. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: A short follow-up. Cancer Biomark 2010;6:63-72.
  4. Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem 2007;22:57-60.
  5. Fu Y, Li H. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis. Med Sci Monit 2016;22:3154-3162.
  6. Ratib O, Phelps ME, Huang SC, Henze E, Selin CE, Schelbert HR. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med 1982;23:577-586.
  7. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003;23:315-340.
  8. Lei L, Wang X, Chen Z. PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer. Adv Clin Exp Med 2016;25:377-382.
  9. Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P, Fini M, Giardino R. “Tumor marker guided” salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother 2003;57:452-459.
  10. Xiao Y, Wang L, Jiang X, She W, He L, Hu G. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis. Nucl Med Commun 2016;37:1180-1188.
  11. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. (eds). SEER Cancer Statistics Review, 1975-2012,
  12. National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer. gov/csr/1975_2012/
  13. Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D’Amico DF. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res